Bogdan Marcu

Dr. Bogdan Marcu

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2026 in Medicina
Verified
Journal Article
Open access
PDF file
VEVasilica Enache
Vasilica Enache
Dan Cristian PopescuDan Cristian Popescu
Dan Cristian Popescu
BMBogdan Marcu
Bogdan Marcu
Mara DiaconuMara Diaconu
Mara Diaconu
NANechita Alexandru
Nechita Alexandru
Metabolic syndrome came to the attention of the scientific community several decades ago, and its definition has undergone multiple changes over time. It is currently defined by the coexistence of hypertension, central obesity, dyslipidemia, and impaired glucose metabolism, with insulin resistance, chronic inflammation, and oxidative stress representing important underlying pathophysiological mechanisms. The latter two processes are major promoters of the onset and progression of atherosclerosis. In parallel, many individuals develop metabolic dysfunction-associated steatotic liver disease (MASLD), formerly called non-alcoholic fatty liver disease (NAFLD). Growing evidence indicates that MASLD may interact bidirectionally with cardiovascular, renal, and metabolic dysfunction and may contribute to cardiometabolic risk. These observations have prompted proposals for a broader cardio–reno–hepato–metabolic axis. However, MASLD is not currently included in the established cardiovascular-kidney-metabolic (CKM) definition or staging system, and its incorporation remains an evolving conceptual extension. Prediabetes is a reversible condition characterized by abnormal glucose levels that do not meet the diagnostic criteria for diabetes. The American Diabetes Association defines prediabetes as glycated hemoglobin (HbA1c) = 5.7–6.4%, fasting plasma glucose = 100–125 mg/dL, or two-hour plasma glucose during an oral glucose tolerance test = 140–199 mg/dL. This comprehensive review examines traditional and genetic risk determinants, shared pathophysiological mechanisms, diagnostic strategies, clinical manifestations, emerging phenotypes, circulating microRNAs as non-invasive biomarkers, complications, and the principal therapeutic strategies, including diet, exercise, and pharmacotherapy. Particular attention is given to the recent approvals of resmetirom and semaglutide for metabolic dysfunction-associated steatohepatitis and to the expanding roles of sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists and non-steroidal mineralocorticoid receptor antagonists. Cardiovascular, renal, metabolic, and hepatic disorders are frequently present in the same patient. Other individuals may develop this high-risk cluster over time. The aim of this article is to define the interplay between different metabolic conditions and to outline the best approach to diagnosis, monitoring, and effective integrated therapy.

27 October 2026 in Epidemiologia
Verified
Journal Article
Open access
PDF file
NANechita Alexandru
Nechita Alexandru
Dan Cristian PopescuDan Cristian Popescu
Dan Cristian Popescu
Mara DiaconuMara Diaconu
Mara Diaconu
BMBogdan Marcu
Bogdan Marcu
VEVasilica Enache
Vasilica Enache
Cardiovascular disease (CVD) is the most important contributor to global mortality and disability, and its aetiology extends well beyond the classical behavioural and metabolic risk factors. This exploratory narrative review examines selected international evidence on air and water pollution, geological and urban exposures, socioeconomic disadvantage, and working conditions in mining, metallurgy, automotive manufacturing, agriculture and sedentary or psychosocially demanding occupations. Central and Eastern Europe, including Romania, is considered as a contextual example rather than a separately studied population. We also sought to describe the mechanisms through which specific risk factors trigger harmful pathophysiological responses. Associations differ by exposure definition, outcome, study design and source population. The review identifies prevention and research priorities while acknowledging its purposive evidence selection, heterogeneous populations and lack of a systematic search or new pooled analysis. Population-specific longitudinal and intervention studies are needed to quantify joint effects and the cardiovascular benefits of structural prevention.

30 September 2026 in Medicina
Verified
Journal Article
Open access
PDF file
NANechita Alexandru
Nechita Alexandru
Dan Cristian PopescuDan Cristian Popescu
Dan Cristian Popescu
Mara DiaconuMara Diaconu
Mara Diaconu
APAdrian-Claudiu Popa
Adrian-Claudiu Popa
BMBogdan Marcu
Bogdan Marcu
VEVasilica Enache
Vasilica Enache
Accelerated atherosclerosis (AA) denotes a disproportionately early and rapid progression of arterial atheroma unpredictable by standard tools. Clinicians often rely on simplified frameworks for cardiovascular risk assessment, which may overlook genetic and pathological conditions associated with AA. Some of these are well established, others are considered future therapy targets. This review examines the conditions in which AA is most firmly established, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), antiphospholipid syndrome, chronic kidney disease (CKD), human immunodeficiency virus (HIV), diabetes mellitus, and psoriasis. We also examined the importance of genetic determinants of AA, with particular emphasis on clonal hematopoiesis of indeterminate potential (CHIP) and lipoprotein (a) (Lp(a)); contemporary imaging-based detection and monitoring; the diagnostic role of circulating non-coding microRNAs; and complementary protein biomarkers of residual inflammatory risk. After identifying biomarkers of increased cardiovascular risk and possible AA, clinicians should assess atherosclerotic disease directly using the available imaging techniques, most of which are non-invasive. The clinical consequences of AA are discussed and a comprehensive review of the therapeutic options is provided to offer a practical approach.